Citation Impact
Citing Papers
Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts
2010 StandoutNobel
Endosomal TLR signaling is required for anti-nucleic acid and rheumatoid factor autoantibodies in lupus
2009 StandoutNobel
Trained immunity: A program of innate immune memory in health and disease
2016 StandoutScience
Selective blockade of inhibitory Fcγ receptor enables human dendritic cell maturation with IL-12p70 production and immunity to antibody-coated tumor cells
2005 StandoutNobel
The gut microbiota and host health: a new clinical frontier
2015 Standout
PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity
2017 StandoutNature
Hallmarks of Cancer: The Next Generation
2011 Standout
The urgent need to recover MHC class I in cancers for effective immunotherapy
2016
The effects of antibiotics on the microbiome throughout development and alternative approaches for therapeutic modulation
2016
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries
2021 Standout
EAU Guidelines on Non–Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016
2016 Standout
Elements of cancer immunity and the cancer–immune set point
2017 StandoutNature
Inflammation and cancer
2002 StandoutNature
Delayed graft function in kidney transplantation
2004 Standout
Cancer Immunosurveillance and Immunoediting: The Roles of Immunity in Suppressing Tumor Development and Shaping Tumor Immunogenicity
2006
Necroptosis and its role in inflammation
2015 StandoutNature
Correlates of physical activity: why are some people physically active and others not?
2012 Standout
The Effect of Infections on Susceptibility to Autoimmune and Allergic Diseases
2002 Standout
The effect of age and gender on bladder cancer: a critical review of the literature
2009
TLR-dependent and TLR-independent pathways of type I interferon induction in systemic autoimmunity
2007 StandoutNobel
VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer
2017 StandoutNobel
Bladder cancer in the elderly
2009
Cholinergic agonists attenuate renal ischemia–reperfusion injury in rats
2008
Focus on bladder cancer
2004
Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial
2005
Apoptosis by Death Factor
1997 Standout
Development of Lupus-like Autoimmune Diseases by Disruption of the PD-1 Gene Encoding an ITIM Motif-Carrying Immunoreceptor
1999 StandoutNobel
The Human Intestinal Microbiome in Health and Disease
2016 Standout
Molecular cloning and expression of the fas ligand, a novel member of the tumor necrosis factor family
1993 Standout
TNF-α mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity
2002 Standout
Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis
1992 StandoutNature
Interdependent IL-7 and IFN-γ signalling in T-cell controls tumour eradication by combined α-CTLA-4+α-PD-1 therapy
2016 StandoutNobel
Macrophage Diversity Enhances Tumor Progression and Metastasis
2010 Standout
A New Equation to Estimate Glomerular Filtration Rate
2009 Standout
EAU Guidelines on Non–Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2013
2013 Standout
A New Multimodality Technique Accurately Maps the Primary Lymphatic Landing Sites of the Bladder
2009
Impact of Total Lymph Node Count and Lymph Node Ratio on Staging and Survival after Pancreatectomy for Pancreatic Adenocarcinoma: A Large, Population-Based Analysis
2007
Mycobacterial antigens attenuate late phase response, airway hyperresponsiveness, and bronchoalveolar lavage eosinophilia in a mouse model of bronchial asthma
2001
Histologic variants of urothelial carcinoma: differential diagnosis and clinical implications
2006
Matrix Metalloproteinases: Regulators of the Tumor Microenvironment
2010 Standout
Bladder cancer
2016 Standout
Immunity, Inflammation, and Cancer
2010 Standout
Inflammasome-activated gasdermin D causes pyroptosis by forming membrane pores
2016 StandoutNature
Cancer immunotherapy comes of age
2011 StandoutNature
The Fas Death Factor
1995 StandoutScience
Pancreatic Cancer
2010 Standout
Repertoires of Autophagy in the Pathogenesis of Ocular Diseases
2015 Standout
Cytokine Panel for Response to Intravesical Therapy (CyPRIT): Nomogram of Changes in Urinary Cytokine Levels Predicts Patient Response to Bacillus Calmette-Guérin
2015
Tumour necrosis factor and cancer
2009
Points of control in inflammation
2002 StandoutNature
Inflammation, Atherosclerosis, and Coronary Artery Disease
2005 Standout
Micropapillary urothelial carcinoma of the urinary bladder: a clinicopathological analysis of 72 cases
2010
Chromatin–IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors
2002 StandoutNature
Mechanisms of BCG immunotherapy and its outlook for bladder cancer
2018
The mechanism of action of BCG therapy for bladder cancer—a current perspective
2014
Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial
2004
Role of bacillus Calmette–Guérin in the treatment of advanced melanoma
2011
Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy
2016 StandoutNobel
Bacillus Calmette–Guérin treatment of non‐muscle invasive bladder cancer
2010
EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non–Muscle-invasive Stage Ta–T1 Urothelial Bladder Cancer Patients Treated with 1–3 Years of Maintenance Bacillus Calmette-Guérin
2015
Prognostic factors and outcome in patients with T1 high‐grade bladder cancer: can we identify patients for early cystectomy?
2011
Immunotherapy for the Treatment of Urothelial Carcinoma
2016
Definitions, End Points, and Clinical Trial Designs for Non–Muscle-Invasive Bladder Cancer: Recommendations From the International Bladder Cancer Group
2016
EFFICACY AND SAFETY OF VALRUBICIN FOR THE TREATMENT OF BACILLUS CALMETTE-GUERIN REFRACTORY CARCINOMA IN SITU OF THE BLADDER
2000
Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death.
1992 StandoutNobel
Fas ligand mediates activation-induced cell death in human T lymphocytes.
1995 StandoutNobel
TNF-α mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity
2002 Standout
Defining Progression in Nonmuscle Invasive Bladder Cancer: It is Time for a New, Standard Definition
2013
Microorganisms and Cancer: Quest for a Therapy
2003
Workshop R: Tumor Immunology, Abstract R1 bis R30
2001
The Role of Tumor-Free Status in Repeat Resection Before Intravesical Bacillus Calmette-Guerin for High Grade Ta, T1 and CIS Bladder Cancer
2010
Bladder Cancer
2020 Standout
Guideline for the Management of Nonmuscle Invasive Bladder Cancer (Stages Ta, T1, and Tis): 2007 Update
2007
Acetylcholine-Synthesizing T Cells Relay Neural Signals in a Vagus Nerve Circuit
2011 StandoutScience
Immune Complexes Present in the Sera of Autoimmune Mice Activate Rheumatoid Factor B Cells
2000
Activation of Natural Killer T Cells by α-Galactosylceramide Rapidly Induces the Full Maturation of Dendritic Cells In Vivo and Thereby Acts as an Adjuvant for Combined CD4 and CD8 T Cell Immunity to a Coadministered Protein
2003 StandoutNobel
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
2011 StandoutScience
Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients
2008 StandoutNobel
IFN-α–Induced Apoptosis in Hepatocellular Carcinoma Involves Promyelocytic Leukemia Protein and TRAIL Independently of p53
2009
PROSPECTIVELY PACKAGED LYMPH NODE DISSECTIONS WITH RADICAL CYSTECTOMY: EVALUATION OF NODE COUNT VARIABILITY AND NODE MAPPING
2004
The Yin and Yang of T Cell Costimulation
1995 StandoutScienceNobel
Identification of simple arylfluorosulfates as potent agents against resistant bacteria
2021 StandoutNobel
Cell death induced by acute renal injury: a perspective on the contributions of apoptosis and necrosis
2003
Lpr and gld: Single Gene Models of Systemic Autoimmunity and Lymphoproliferative Disease
1991
Enhanced Dendritic Cell Maturation by TNF-α or Cytidine-Phosphate-Guanosine DNA Drives T Cell Activation In Vitro and Therapeutic Anti-Tumor Immune Responses In Vivo
2000
Bradykinin B1 and B2 receptors both have protective roles in renal ischemia/reperfusion injury
2007 StandoutNobel
Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline
2017
CD4+/CD8+ macrophages infiltrating at inflammatory sites: a population of monocytes/macrophages with a cytotoxic phenotype
2005
RNA-associated autoantigens activate B cells by combined B cell antigen receptor/Toll-like receptor 7 engagement
2005
Refining Patient Selection for Neoadjuvant Chemotherapy before Radical Cystectomy
2013
Therapeutic cancer vaccines
2015
Intravesical Therapy for Non-muscle Invasive Bladder Cancer-Current and Future Options in the Age of Bacillus Calmette-Guerin Shortage.
2019
Adjuvant-Enhanced Antibody Responses in the Absence of Toll-Like Receptor Signaling
2006 StandoutScienceNobel
CAR T cell immunotherapy for human cancer
2018 StandoutScience
Prostaglandin E2 is a selective inducer of interleukin-12 p40 (IL-12p40) production and an inhibitor of bioactive IL-12p70 heterodimer
2001
Canadian Association of Radiologists consensus guidelines for the prevention of contrast-induced nephropathy: update 2012.
2007
Use of Fluorescence In Situ Hybridization to Predict Response to Bacillus Calmette-Guérin Therapy for Bladder Cancer: Results of a Prospective Trial
2012
Works of Michael A. O’Donnell being referenced
Role of IL-12 in the Induction and Potentiation of IFN-γ in Response to Bacillus Calmette-Guerin
1999
The Role of Bacillus Calmette-Guérin in the Treatment of Non–Muscle-Invasive Bladder Cancer
2009
Sentinel Lymph Node Mapping of Invasive Urinary Bladder Cancer in Animal Models Using Invisible Light
2007
Management of stage T1 tumors of the bladder: International Consensus Panel
2005
The significance of lymphovascular invasion in transurethral resection of bladder tumour and cystectomy specimens on the survival of patients with urothelial bladder cancer
2008
Consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer
2015
Recombinant bacillus Calmette-Guérin (BCG) expressing interferon-alpha 2B enhances human mononuclear cell cytotoxicity against bladder cancer cell lines in vitro
2009
Protective Effect of HMG-CoA Reductase Inhibitor on Experimental Renal Ischemia-Reperfusion Injury
2002
Impact of Previous Bacille Calmette-Guérin Failure Pattern on Subsequent Response to Bacille Calmette-Guérin Plus Interferon Intravesical Therapy
2008
Role of neutrophils in BCG immunotherapy for bladder cancer
2008
Immunotherapy of Experimental Bladder Cancer with Recombinant BCG Expressing Interferon-γ
2004
BCG immunotherapy of bladder cancer: 20 years on
1999
NEMO/IKKγ regulates an early NF-κB-independent cell-death checkpoint during TNF signaling
2009
Role of Th1 and Th2 cytokines in BCG-induced IFN-γ production: cytokine promotion and simulation of BCG effect
2003
Regulation of the anti-Sm autoantibody response in systemic lupus erythematosus mice by monoclonal anti-Sm antibodies.
1990
Experience with Sequential Intravesical Gemcitabine and Docetaxel as Salvage Therapy for Non-Muscle Invasive Bladder Cancer
2016
Nephropathy requiring dialysis after percutaneous coronary intervention and the critical role of an adjusted contrast dose
2002
Final results from a national multicenter phase II trial of combination bacillus Calmette-Guérin plus interferon α-2B for reducing recurrence of superficial bladder cancer☆
2006
Interferon alfa in the treatment paradigm for non–muscle-invasive bladder cancer
2013
Clinical Trial Design for the Development of New Therapies for Nonmuscle-invasive Bladder Cancer: Report of a Food and Drug Administration and American Urological Association Public Workshop
2013
Predicting Response to Intravesical Bacillus Calmette-Guérin Immunotherapy: Are We There Yet? A Systematic Review
2018
Economic interventions to promote physical activity
2004
Optimizing BCG therapy
2009
The role of neutrophils and TNF-related apoptosis-inducing ligand (TRAIL) in bacillus Calmette–Guérin (BCG) immunotherapy for urothelial carcinoma of the bladder
2009
Bacillus Calmette-Guerin strain may not effect recurrence-free survival when used intravesically with interferon-alpha2b for non–muscle-invasive bladder cancer
2016
The Essential Role of Interferon-γ During Interleukin-12 Therapy for Murine Transitional Cell Carcinoma of the Bladder
2004
Anti-interleukin-10R1 monoclonal antibody in combination with bacillus Calmette–Guérin is protective against bladder cancer metastasis in a murine orthotopic tumour model and demonstrates systemic specific anti-tumour immunity
2014
SALVAGE INTRAVESICAL THERAPY WITH INTERFERON-α2B PLUS LOW DOSE BACILLUS CALMETTE-GUERIN IS EFFECTIVE IN PATIENTS WITH SUPERFICIAL BLADDER CANCER IN WHOM BACILLUS CALMETTE-GUERIN ALONE PREVIOUSLY FAILED
2001
Bladder Cancer Immunotherapy: BCG and Beyond
2012
INTERIM RESULTS FROM A NATIONAL MULTICENTER PHASE II TRIAL OF COMBINATION BACILLUS CALMETTE-GUERIN PLUS INTERFERON ALFA-2B FOR SUPERFICIAL BLADDER CANCER
2004
Pathophysiological role of T lymphocytes in renal ischemia-reperfusion injury in mice
2000
Treatment options for BCG failures
2006
Mycobacterium bovisbacillus Calmette–Guérin (BCG) induces human CC- and CXC-chemokinesin vitroandin vivo
2006
Bacillus Calmette-Guérin With or Without Interferon α-2b and Megadose Versus Recommended Daily Allowance Vitamins During Induction and Maintenance Intravesical Treatment of Nonmuscle Invasive Bladder Cancer
2010
Usefulness of the Spanish Urological Club for Oncological Treatment Scoring Model to Predict Nonmuscle Invasive Bladder Cancer Recurrence in Patients Treated With Intravesical Bacillus Calmette-Guérin Plus Interferon-α
2010
Specificity and idiotypic analysis of a monoclonal anti-Sm antibody with anti-DNA activity.
1985
IFN-alpha 2B enhances Th1 cytokine responses in bladder cancer patients receiving Mycobacterium bovis bacillus Calmette-Guérin immunotherapy.
1999
Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand
2004
Anti-Interleukin-10R1 Monoclonal Antibody Enhances Bacillus Calmette-Guérin Induced T-Helper Type 1 Immune Responses and Antitumor Immunity in a Mouse Orthotopic Model of Bladder Cancer
2012
Factors Affecting Response to Bacillus Calmette-Guérin Plus Interferon for Urothelial Carcinoma in Situ
2011
The Impact of Age on the Response of Patients With Superficial Bladder Cancer to Intravesical Immunotherapy
2006
Multi-Institution Evaluation of Sequential Gemcitabine and Docetaxel as Rescue Therapy for Nonmuscle Invasive Bladder Cancer
2019
Recognition and Treatment of BCG Failure in Bladder Cancer
2011
Eradication of murine bladder carcinoma by intratumor injection of a bicistronic adenoviral vector carrying cDNAs for the IL-12 heterodimer and its inhibition by the IL-12 p40 subunit homodimer.
1997
RecombinantMycobacterium bovisbacillus Calmette-Guérin (BCG) expressing mouse IL-18 augments Th1 immunity and macrophage cytotoxicity
2004
Bacillus Calmette-Guérin Immunotherapy for Superficial Bladder Cancer
1995
Role of IL-12 in the induction and potentiation of IFN-gamma in response to bacillus Calmette-Guérin.
1999
SUPERFICIAL BLADDER CANCER: THE ROLE OF INTERFERON-alpha
1998
CLINICAL AND PATHOLOGICAL CHARACTERISTICS OF MICROPAPILLARY TRANSITIONAL CELL CARCINOMA: A HIGHLY AGGRESSIVE VARIANT
2000
Extent of Pelvic Lymphadenectomy and Its Impact On Outcome in Patients Diagnosed With Bladder Cancer: Analysis of Data From the Surveillance, Epidemiology and End Results Program Data Base
2003
Bacillus calmete-guérin plus interferon-α2B intravesical therapy maintains an extended treatment plan for superficial bladder cancer with minimal toxicity
2003